home / stock / iphyf / iphyf short
Short Information | Innate Pharma (OTCMKTS:IPHYF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 37,951 |
Total Actual Volume | 41,852 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 19 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,898 |
Average Short Percentage | 84.38% |
Is there a IPHYF Short Squeeze or Breakout about to happen?
See the IPHYF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-02-2024 | $2.43 | $2.65 | $2.65 | $2.43 | 300 | 200 | 66.67% |
03-28-2024 | $2.39 | $2.58 | $2.65 | $2.39 | 800 | 300 | 37.5% |
12-04-2023 | $2.44 | $2.44 | $2.48 | $2.44 | 500 | 400 | 80% |
10-16-2023 | $2.31 | $2.31 | $2.31 | $2.31 | 500 | 500 | 100% |
08-31-2023 | $3 | $3 | $3 | $3 | 1,000 | 1,000 | 100% |
06-21-2023 | $3.36 | $3.36 | $3.36 | $3.36 | 300 | 300 | 100% |
06-08-2023 | $3.33 | $3.37 | $3.37 | $3.33 | 300 | 200 | 66.67% |
05-31-2023 | $0 | $2.93 | $0 | $0 | 2 | 1 | 50% |
05-04-2023 | $2.89 | $2.89 | $2.89 | $2.89 | 100 | 100 | 100% |
05-03-2023 | $2.87 | $2.87 | $2.87 | $2.87 | 100 | 100 | 100% |
04-27-2023 | $2.88 | $2.88 | $2.88 | $2.88 | 200 | 200 | 100% |
04-25-2023 | $2.95 | $2.95 | $2.95 | $2.95 | 200 | 100 | 50% |
12-22-2022 | $2.65 | $2.65 | $2.65 | $2.65 | 25,500 | 25,500 | 100% |
12-14-2022 | $2.32 | $2.32 | $2.32 | $2.32 | 100 | 100 | 100% |
11-04-2022 | $2.0835 | $2.0835 | $2.0835 | $2.0835 | 3,000 | 3,000 | 100% |
10-19-2022 | $2.0889 | $2.0889 | $2.0889 | $2.0889 | 150 | 150 | 100% |
10-13-2022 | $2 | $2.07 | $2.07 | $2 | 3,500 | 3,000 | 85.71% |
10-12-2022 | $1.95 | $1.95 | $1.95 | $1.95 | 5,099 | 2,599 | 50.97% |
09-27-2022 | $0 | $2 | $0 | $0 | 1 | 1 | 100% |
09-20-2022 | $2.58 | $2.58 | $2.58 | $2.58 | 200 | 200 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models Prec...